Bluejay Diagnostics (NASDAQ:BJDX) Raised to Hold at Wall Street Zen

Bluejay Diagnostics (NASDAQ:BJDX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Bluejay Diagnostics Stock Performance

Shares of Bluejay Diagnostics stock opened at $0.83 on Friday. Bluejay Diagnostics has a 1 year low of $0.82 and a 1 year high of $16.68. The company has a market capitalization of $3.72 million, a P/E ratio of -0.12 and a beta of 0.91. The company’s fifty day moving average is $1.07 and its two-hundred day moving average is $1.95.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its earnings results on Wednesday, August 12th. The company reported ($1.12) EPS for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Insider Activity at Bluejay Diagnostics

In other news, major shareholder Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the sale, the insider owned 92,055 shares of the company’s stock, valued at $128,877. The trade was a 27.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is owned by hedge funds and other institutional investors.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.